Ocugen Q2 FY26 net loss widens to $24.88 million; revenue rises to $1.49 million

Reuters2026/08/06 11:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ocugen posted a GAAP net loss of USD 24.88 million, or USD 0.07 per share, for Q2 2026, versus a loss of USD 14.74 million, or USD 0.05 per share, a year earlier.
Revenue edged up to USD 1.49 million from USD 1.37 million, while operating loss widened to USD 16.44 million from USD 13.8 million.
Operating expenses rose to USD 17.93 million from USD 15.17 million, led by RD costs of USD 10.69 million and GA of USD 7.24 million.
Cash, cash equivalents and restricted cash climbed to USD 100.4 million at June 30 from USD 32.2 million at March 31, following a USD 130 million 6.75% Convertible Senior Notes due 2034 offering.
FDA cleared a Phase 3 OCU410 trial in geographic atrophy and granted RMAT status; top-line data remain targeted for OCU400 in 1Q 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ocugen Q2 FY26 net loss widens to $24.88 million; revenue rises to $1.49 million

You may also like

Crypto prices